- Home
- FORR vs QNCX Comparison
FORR vs QNCX Comparison
Compare FORR & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FORR | QNCX |
|---|---|---|
| Founded | 1983 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.9M | 167.0M |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FORR | QNCX |
|---|---|---|
| Price | $7.92 | $3.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 98.0K | ★ 860.5K |
| Earning Date | 02-10-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $403,871,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.60 | $0.72 |
| 52 Week High | $15.80 | $4.55 |
Technical Indicators
Market Signals| Indicator | FORR | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 53.01 | 55.42 |
| Support Level | $8.09 | $2.85 |
| Resistance Level | $8.59 | $3.15 |
| Average True Range (ATR) | 0.30 | 0.31 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 45.30 | 71.55 |
Price Performance
Historical ComparisonAbout FORR Forrester Research Inc.
Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.